Ligand Pharmaceuticals Stock Earnings Reports

Ligand reported strong Q1 2026 results driven by royalty revenue growth (royalty revenue +56% YoY; total revenue $52M; adjusted EPS $1.63, +23% YoY). Management highlighted the success of their 2022 strategic shift to a pure royalty aggregation model, scaling from ~7 to 15 commercial assets and closing 18 deals in three years while cutting operating costs and improving operating leverage. Key growth drivers in the quarter included Filspari (now Ligand's largest commercial royalty following expanded approval into FSGS), Ohtuvayre, Qarziba and early traction from Zelsuvmi. Palvella’s QTORIN rapamycin delivered positive Phase III SELVA results in microcystic lymphatic malformations and Palvella plans an NDA submission in H2 2026. Ligand announced the planned acquisition of XOMA Royalty (expected close in Q3), which management says will be immediately accretive and materially scale and diversify the portfolio—adding 7 marketed products and nearly doubling Phase II/III assets. Management reiterated 2026 guidance assuming XOMA closes in Q3: total revenue $270M–$310M, royalty revenue $225M–$250M, and adjusted EPS $8.50–$9.50, and noted the XOMA transaction is expected to add ~$0.50 of adjusted EPS in 2026 and ~$1.50 in 2027. Balance sheet strength (~$780M cash & investments + $200M undrawn revolver) and tax attributes from XOMA are expected to support continued nondilutive portfolio expansion ($150M–$250M annual target deployment).